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Discussion Although the IgV Ovar Rhineland proved to 
have some structural problems with recruitment and pro-
spective data collection, cytoreduction rates and outcome 
of patients prove treatment of patients in expert centers 
is superior to the national and international mean. There-
fore, a new quality initiative will be started to bring more 
awareness to women and to their gynecologists and gen-
eral practitioners of just how important a good referral 
strategy is.
Keywords Ovarian cancer · High-volume hospitals · 
Quality · Cytoreduction · Survival
Introduction
With 75 % ovarian cancer is still typically diagnosed at late 
stages, at this point, peritoneal carcinosis has most often 
spread to all quarters of the abdomen and/or to the pleu-
ral surfaces (FIGO IIIC or IVA). These women have a poor 
prognosis despite all efforts and have a 5-year survival rate 
of <25 %. Over three quarters of these patients present with 
serous papillary histology (Heintz et al. 2006).
Therapy of the disease is a combination of surgery and 
chemotherapy. Agents used for chemotherapy have been 
platinum, usually carboplatin, and a taxane, most often 
paclitaxel. Despite a few changes in regimen or (interna-
tionally) in sequence and route of application from intra-
venous to adding intraperitoneal, this has not changed for 
more than a decade (du Bois et al. 2003, 2010; Armstrong 
et al. 2006; Polcher et al. 2009; Pignata et al. 2014).
Prognostic factors are age, performance status, stage, 
histologic type, grading, pN1 status and the complete-
ness of cytoreduction (Chi et al. 2001). Whereas the first 
six parameters are inherent, cytoreduction is influenced 
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not only by the sites of the metastatic peritoneal tumor but 
greatly by the abilities of the individual surgeon and by the 
infrastructure available at the hospital (Kuhn et al. 2001; 
Crawford et al. 2005; Chi et al. 2006).
Researchers, mainly from the USA, but also from Ger-
many, have shown treatment in hospitals with an interdis-
ciplinary approach of the gynecologic oncologist as a sur-
geon with visceral surgeons and urologists improves the 
outcome of patients with ovarian cancer (Wimberger et al. 
2007; Bristow et al. 2009). Equally important to the struc-
ture and case volume of the hospital is the experience and 
case volume of the operating gynecological surgeon (du 
Bois et al. 2009; Bristow et al. 2014).
Unfortunately, besides these well-published and 
researched facts, in Germany treatment of patients with 
late-stage ovarian cancer is not restricted to specialized 
centers. Basically, any surgeon’s belief in his or her own 
abilities qualifies for the undertaking of treatment of these 
patients, in some cases producing surgical outcomes of low 
quality with impaired survival of the patient.
In 2005, by initiative of the public health insurances, 
specialized gynecologic oncologists from six centers for 
treatment of ovarian cancer in the Rhineland came together 
with 21 health insurers forming the idea of an integrated 
care program (IgV) for patients with ovarian cancer.
The program was implemented to increase the amount 
of patients being treated in hospitals with high quality of 
surgical performance and in hospitals with adequate infra-
structure, therefore increasing the rate of successfully com-
pletely cytoreduced patients.
Results from the “Integrated care in ovarian cancer 
(“IgV Ovar”) Rhineland” and outcomes of patients from 
three participating hospitals will be presented here.
Methods
Criteria of quality were developed with international spe-
cialists of the field. They were laid down in a contract with 
the health insurance companies for hospitals wanting to 
take part in the initiative. These included structural crite-
ria of the clinic as a whole for measurement of the inter-
disciplinary work with visceral surgeons and urologists, 
structural quality criteria for the gynecologic department 
for insuring operations by board-certified gynecologic sur-
geons, and number of carried out operations on patients 
with ovarian cancer in the last years per department and per 
surgeon and for chemotherapy application.
After diagnosis of ovarian cancer, each patient insured 
with any of the participating health insurances was asked 
whether she would like to participate in this quality ini-
tiative. If the patient was interested and registered per 
informed consent, the referring gynecologist was asked 
whether he/she was willing to cooperate, integrating the 
practice into the after-treatment clinical follow-up, with the 
patient presenting at the clinic and the referring gynecolo-
gist one time over the other.
Similar to other integrated programs (e.g., DMP 
Mamma), the referring gynecologist was asked to register 
with the initiative and would receive a fee for completing 
some follow-up forms on seeing the patients. Patients were 
to answer some Quality of life (QoL) questionnaires on 
presenting for clinical follow-up. All generated data were 
to be sent to the individual health insurance of the patient 
per fax.
To prove the idea, treatment of ovarian cancer patients 
in centers of experience would lead to better outcome of 
these patients, and to prove the principal idea of a central-
ized care for these patients, three of the participating hos-
pital agreed to pool their data for treatment of patients with 
all stages of ovarian cancer in their institutions. To analyze 
quality of treatment, focus was laid on adjuvant treated 
patients with advanced stages (FIGO IIB–IV) since these 
patients represent a homogenously treated group. More 
analysis was done for FIGO IIIC patients, for these are pre-
senting with surgically challenging conditions.
Data of all patients, treated in the Department of Obstet-
rics and Gynecology of the Helios Klinikum in Krefeld, the 
Evangelisches Krankenhaus in Düsseldorf and the Univer-
sity Hospital in Bonn were collected retrospectively. Since 
all hospitals are certified by the Deutsche Krebsgesells-
chaft (DKG) as “Gynäkologische Krebszentren”, signifi-
cant parts of the follow-up were available, and missing data 
were completed.
Statistical analysis was performed using the IBM pro-
gram SPSS 22, IBM, Ehningen, Germany.
Results
Data of all patients surgically treated with ovarian can-
cer in the three hospitals between 2006 and 2012, 1038 
patients in total, were collected (see Table 1). Out of 505 
patients with adjuvant treatment, 307 patients were treated 
Table 1  Collective of patients





Other than EOC 81
Total 1038
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with advanced disease (IIB–IV) used for this analysis (see 
Table 2).
The median age was 63.4 years (range 25–100 years), 
79 % presenting with FIGO III disease. ASA classifica-
tion (grading of patients for surgical procedures of the 
American Society of Anesthesiologists) was used as sur-
rogate marker for performance status and was ASA 2 in 
61 % and ASA 3 in 24 % of cases. Twenty-four percent-
age of patients presented with Grade 3 tumors, and 38 % 
had lymph node involvement. Fifty percentage of patients 
underwent systematic lymphonodectomy, in which 9.5 % 
bulky nodes were removed. Median number of removed 
nodes was 38 (95 % CI 7–138). Median operation time was 
290 min (95 % CI 29–695 min).
Fifty percentage of patients were cytoreduced to no 
residual tumor, and 28 % had residual tumor ≤1 cm 
(Table 2).
Median follow-up was 32.7 months (95 % CI 0.5–
100 months). Progression-free survival (PFS) was 
23.1 months (95 % CI 20.0–26.1 months) (Fig. 1) and 
overall survival (OS) was 53.6 months (95 % CI 41.6–
65.5 months) in patients with stage IIB–IV (Fig. 2). To 
this group of adjuvant patients, clinic A contributed 73 out 
Table 2  Patient characteristics and postoperative status
FIGO IIB–IV
Age
Mean 63.37 (24.96–99.93) years
FIGO (IIB–IV) 307
IIB–C 18 (5.9 %)
IIIA 8 (2.6 %)
IIIB 35 (11.4 %)
IIIC 198 (64.5 %)
IV 48 (15.6 %)
ASA
1 18 (5.9 %)
2 187 (60.9 %)
3 73 (23.8 %)
n.a. 4 (1.3 %)
Grading
1 2 (0.7 %)
2 108 (35.2 %)
3 195 (63.5 %)
n.a. 2 (0.7 %)
Nodal status
pN0 66 (21.5 %)
pN1 118 (38.4 %)
pNx 102 (33.2 %)
n.a. 21 (6.8 %)
Cytoreduction
Complete 155 (50.5 %)
≤1 cm 87 (28.3 %)
>1 cm 65 (21.2 %)
Fig. 1  Progression free survival FIGO IIB-IV in months: PFS in 307 
patients with FIGO IIB–IV ovarian cancer was 23.1 months (95 % CI 
20.0–26.1 months)
Fig. 2  Overall survival FIGO IIB-IV in months: OS in 307 patients 
with FIGO IIB–IV ovarian cancer was 53.6 months (95 % CI 41.6–
65.5 months)
Table 3  Progression-free survival in months of 198 patients with 
FIGO IIIC ovarian cancer stratified by cytoreduction
PFS Cytoreduction Median
Months 95 %-CI
FIGO IIIC No residual tumor 28.977 16.241–41.714
≤1 cm residual tumor 18.858 15.243–22.473
>1 cm residual tumor 16.263 13.099–19.426
All 21.027 18.027–24.026
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of 156 patients with stage FIGO IIB–IV operated on dur-
ing this time, clinic B 137 out of 156 and clinic C 97 out 
of 107. All three centers are therefore very much equal in 
their hospital volume for advanced ovarian cancer surgery, 
and survival time did not differ between the clinics (OS 
p = 0.963; PFS p = 0.327).
Patients with FIGO IIIC (n = 198) were completely 
cytoreduced in 92 cases (46.46 %), and 61 patients (30.81 %) 
were cytoreduced to ≤1 cm (Table 3). PFS was 21 months 
(95 % CI 18–24 months), 28 months if completely cytore-
duced (95 % CI 16.2–41.7 months; p = 0.001), 18.9 months 
(95 % CI 15.2–22.5 months) if a residual tumor of ≤1 cm, 
16.2 months (95 % CI 13.1–19.4 months) if tumor residuals 
of >1 cm remained (Fig. 3; Table 3).   
 OS was 47.4 months (95 % CI 38.8–55.9 months) 
and 64.9 months (95 % CI 63.6–66.2 months; p = 0.001) 
if completely cytoreduced, 34.1 months (95 % CI 28.9–
39.2 months) if a residual tumor of ≤1 cm, and 34.8 months 
(20.1–49.4 months) if tumor residuals of >1 cm remained 
(Fig. 4; Table 4).
Discussion
Pooled data analysis proved the selection criteria for partic-
ipating hospitals successfully insured the desired improve-
ment of quality of treatment for the patient.
In 2000, 2001, 2004 and 2009, the Arbeitsgemeinschaft 
für Gynäkologische Onkologie Ovar (AGO Ovar) pub-
lished surveys on German hospitals for quality of treat-
ment, using postoperative status of cytoreduction as the 
most important indicator (Hilpert F 2010). Over the sur-
veyed years, the ratio of patients with FIGO II–IV with 
complete cytoreduction was improved from initially less 
than 25 % to about 41 % in the last survey. The participat-
ing IgV hospitals achieved a rate for complete cytoreduc-
tion of 51 % (Fig. 5).
The well-established Munich tumor register reports a 
32 % rate of complete tumor resection for patients with 
stage FIGO IIIC disease (Schmalfeldt et al. 2014). The par-
ticipating IgV hospitals achieved a rate of complete cytore-
duction of 47 % in the same collective.
Data from FIGO IIIC patients show the importance of 
complete tumor resection (Figs. 3, 4). Residual tumor of 
any size will compromise the survival of the patient, since 
there is no statistical difference between gross residual 
tumor and tumor lesions under or over 1 cm (OS 34.1 vs. 
34.8 months, n.s.). This result is to be expected and ties 
in with most published data (Chang and Bristow 2012; 
Keyver-Paik et al. 2013). The same effect of any residual 
tumor was seen for all other stages in the performed analy-
sis outside FIGO IIIC (data not shown).
With high rates of complete cytoreduction, PFS and OS 
were 23.1 and 53.6 months, respectively, for patients with 
FIGO IIB–IV comparing to PFS and OS survival rates in 
literature of 18.2 and 44.1 months in a German collective 
of patients on chemotherapy trials (du Bois et al. 2009). 
International trial results, e.g., ICON7, show a PFS of 17.5 
in the control and 19.9 in the research arm (+bevacizumab) 
and an OS of 30.3 versus 39.7 months for stages I–II high 
risk and IIB–IV (Perren et al. 2011; E Pujade-Lauraine 
2014). In patients with stage FIGO IIIC, the three IgV 
hospitals achieved a PFS of 21 months for all patients and 
29 months when no residual tumor was present. Overall 
survival was 47.4 months for all and 64.9 when no residual 
tumor was present. In ICON7, stage FIGO IIIC patients 
achieved a PFS of 17.5 versus 19.9 and an OS of 58.6 ver-
sus 58.0 months. Although retrospective data, the results of 
the three IgV hospitals are representing an excellent out-
come for patients treated in these hospitals especially con-
sidering the data comes from a non-trial patient collective.
In 2009, du Bois et al. published a meta-analysis of 
surgical outcome comparing operations by board-certified 
gynecologic oncologists to other gynecologic surgeons or 
Fig. 3  Kaplan–Meier function of progression-free survival in 198 
patients with FIGO IIIC ovarian cancer stratified by cytoreduction
Table 4  Overall survival in months of 198 patients with FIGO IIIC 
ovarian cancer stratified by cytoreduction
OS Cytoreduction Median
Months 95 %-CI
FIGO IIIC No residual tumor 64.887 63.578–66.196
≤1 cm residual tumor 34.070 28.920–39.220
>1 cm residual tumor 34.760 20.120–49.400
All 47.376 38.807–55.944
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surgeons of other disciplines, e.g., visceral surgeons (du 
Bois et al. 2009). The data clearly was in favor of the spe-
cialized gynecologic oncologists, showing the knowledge 
of the disease and the acknowledgement of cytoreduction 
as the one most important and influenceable factor in ovar-
ian cancer is the key to a successful operation.
Other published data are showing, when comparing 
surgical effort in experienced centers to less-experienced 
centers, less-experienced centers will significantly under-
perform (all p < 0.0001) in systematic lymphonodectomy, 
bowel surgery and specifically in peritoneal stripping. In 
this analysis, it is most discomforting to see, even basic 
measures, as hysterectomy and bilateral adnexectomy and 
omentectomy are significantly less frequently carried out 
in less-experienced centers (p < 0.0001) (Wimberger et al. 
2007).
A data analysis of 20,600 patients in the USA, pub-
lished in 2010, also proved a statistical correlation 
between case volume for FIGO IIIC and IV patients and 
survival (Bristow et al. 2010). A case volume of >20 cases 
per hospital showed a better overall survival for these 
patients. A later analysis of the same author of almost 
12,000 patients defines high-volume hospitals as hospitals 
with >20 cases, and high-volume physicians as physicians 
with >10 cases (Bristow et al. 2014). Patients treated in 
high-volume hospitals by high-volume physicians have a 
statistically significant better survival than patients treated 
by surgeons with less cases in smaller hospital units. Any 
other combination is also less favorable than the high-vol-
ume combination.
These results were published well after the contracting 
for the IgV Ovar in 2006, but precisely underline the cor-
rectness of the quality strategy applied by the network.
Cost effectiveness was no parameter in the planning 
of the IgV Ovar but data from literature suggest a referral 
strategy to more experienced centers is also cost-effective. 
An American analysis from 2007 showed although treat-
ment in experienced centers may be more expensive ini-
tially (39,957$ vs. 50,652$), when adjusted for QoL and 
survival time, experienced centers were the more cost-
effective healthcare strategy (17,149$ vs. 9893$) (Bristow 
et al. 2007).
This analysis of outcome proves the hypothesis of bet-
tering the treatment of patients in specialized centers, and it 
is probably also a cost-effective strategy, albeit there were 
also some problems in the pilot model of integrated care.
Data collection was not done to the standard aimed for at 
the beginning of this pilot. Quality of data on QoL proved 
insufficient for a comprehensive analysis.
After some thorough investigation into reasons given for 
the reported shortfalls in data collection and recruitment, 
the cardinal points are:
Referring gynecologists were more reserved to the pro-
gram than expected: partly, since participation of their 
patients in this program meant more documentation on an 
occupation already filled with documentation on a daily 
basis, and partly because of a general distrust toward a 
data collection being forwarded to the participating health 
insurers.
On the side of the hospitals’ clinicians, identifying eligi-
ble patients for the program was also some obstacle to over-
come because of the myriad of health insurances, in some 
cases with a very local structure, in the German health sys-
tem. Only patients with the participating insurances were 
to be included in the program, and in some cases, although 
one local branch of an insurance company may take part, 
another local branch of the same insurance might not par-
ticipate. This made it difficult to oversee for the clinician 
to which patient to offer the program without permanently 
carrying a list of the insurances. No private insurance did 
participate in the program.
A negative attitude toward more documentation was 
also one of the stumbling blocks for hospital clinicians. All 
hospitals are certified “Gynäkologische Krebszentren” and 
documentation and follow-up are already done. Hospitals 
employ staff for documentation of patients with gynecolog-
ical cancer and their treatment and follow-up, but with no 
common electronic platform, and using an overcome sys-
tem of paper and fax, double documentation of the same 
patient was necessary.
There was no regular central controlling mechanism 
until the end of the project in 2015. Therefore, regular 
surveillance on data collection and data quality was not 
Fig. 4  Kaplan–Meier function of overall survival in 198 patients 
with FIGO IIIC ovarian cancer stratified by cytoreduction
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established. The decentralized mode of data collection in 
the different clinics, private practice and health insurances 
helped to cover up the lack of complete documentation for 
some extended time.
While the contract was very specific on the qual-
ity assurance of the hospitals structure for treatment for 
patients, it was lacking to specify the quality of structure 
for documentation. It would have been advisable to install a 
case manager for patients on the program in every hospital.
Ovarian cancer still is a disease with a poor progno-
sis. Surgical outcome with complete cytoreduction is the 
one most important prognostic factor for the survival of a 
patient. Too many patients in Germany today are still not 
referred to centers of experience, where an interdisciplinary 
setup and an experienced and well-educated gynecological 
surgeon will see to the success of the cytoreduction. A sub-
optimal referral strategy still costs life and life-time even 
today in Germany.
The quality initiative “IgV Ovar” in the Rhineland was 
a project set up by some health insurances and initiating 
expert centers of the region and under the consultation of 
international experts in this field. IgV Ovar did successfully 
prove, treatment in expert centers leads to a better outcome 
of patients. Therefore, although not all expectations were 
met, a new initiative will be started soon based on the con-
cluded pilot.
Avoiding double documentation and excessive adminis-
trative detail, we will approach hospitals to come together 
with the assistance of the health insurance companies to 
voluntarily publish their quality indicators of case volume 
and outcomes in a benchmarking system. In return, we will 
initiate an awareness campaign for patients, gynecologists 
and general practitioners publishing the benchmark and 
emphasizing the importance to be treated in expert centers 
when ovarian cancer is diagnosed.
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